Spyre Therapeutics
SYRE
43 hedge funds and large institutions have $31.9M invested in Spyre Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 16 closing their positions.
166% more capital invested
Capital invested by funds: $12M → $31.9M (+$19.9M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1.81% more ownership
Funds ownership: 2.53% → 4.34% (+1.8%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 44 → 43 (-1)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$1.79M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.67M |
| 3 |
VA
VR Adviser
New York
|
+$1.2M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$948K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$929K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.55M |
| 2 |
SCM
Sio Capital Management
New York
|
-$871K |
| 3 |
O
OrbiMed
New York
|
-$521K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$435K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$256K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Two Sigma Advisers
New York
| – | -$61.1K | -8,432 | Closed |
|
|
BCM
52
Bridgeway Capital Management
Houston,
Texas
| – | -$43.5K | -6,000 | Closed |
|
|
ECM
53
ExodusPoint Capital Management
New York
| – | -$34K | -4,699 | Closed |
|
|
FSA
54
Franklin Street Advisors
Chapel Hill,
North Carolina
| – | -$31K | -4,232 | Closed |
|
55
William Blair & Company
Chicago,
Illinois
| – | -$17.5K | -2,412 | Closed |
|
|
RWM
56
Ritholtz Wealth Management
New York
| – | -$12.1K | -1,671 | Closed |
|
57
Bank of America
Charlotte,
North Carolina
| – | -$10.2K | -1,409 | Closed |
|
|
VF
58
Virtu Financial
New York
| – | -$6K | -772 | Closed |
|
59
BNP Paribas Financial Markets
Paris,
France
| – | -$76 | -16 | Closed |
|
SYRE Hedge Fund Activity: Q2 2023 in Review
43 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2023, worth a combined $31.9M — up 166% from $12M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SYRE and 15 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 4 added.
The largest buyer was Fairmount Funds Management, opening a new position worth an estimated $1.79M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $1.55M sold.
- 43 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2023, down from 44 in Q1 2023.
- Funds reported $31.9M of Spyre Therapeutics stock for Q2 2023, up 166% quarter-over-quarter.
- 15 funds opened new Spyre Therapeutics positions in Q2 2023 and 16 closed out, a net change of -1 holder.
- The largest Spyre Therapeutics buyer in Q2 2023 was Fairmount Funds Management, an estimated $1.79M added.
- The largest Spyre Therapeutics seller in Q2 2023 was Bain Capital Life Sciences Investors, an estimated $1.55M sold.
Based on aggregated 13F filings for Q2 2023.